IMPROVE - Investigating Medication Re-Purposing To Reduce Risk Of OVarian Cancer And Extend Survival
Funder
National Health and Medical Research Council
Funding Amount
$430,196.00
Summary
Ovarian cancer is the 6th most common cause of cancer death in women and the proportion of women who die from their disease has not improved substantially over time. This large-scale study will use de-identified data from the Pharmaceutical Benefits Scheme, the Australian Cancer Database and the National Death Index to investigate whether medications commonly used for other conditions can help decrease the risk of ovarian cancer developing or improve survival from ovarian cancer after diagnosis.
The Ovarian Cancer Prognosis And Lifestyle (OPAL) Study: Long-term Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$871,657.00
Summary
Ovarian cancer affects 1500 women each year in Australia and 5-year survival is <45%. Affected women thus face a poor prognosis and often ask what they can do to improve this. There is no direct evidence whether a woman’s lifestyle might influence her outcomes, although data from breast cancer suggest this is possible. The OPAL Study is following 960 women with ovarian cancer to identify whether lifestyle is associated with long-term survival to provide evidence for women with this disease.
Improving Outcomes From Ovarian Cancer: Building The Evidence To Help Women Help Themselves
Funder
National Health and Medical Research Council
Funding Amount
$1,839,772.00
Summary
Ovarian cancer affects 1300 women each year in Australia and 5-year survival is <45%. Women with this cancer thus face a poor prognosis and many ask what they can do to improve this. There is no direct evidence whether a woman’s lifestyle might influence her outcomes, although data from breast cancer suggest this is possible. The OPAL Study will follow 1200 women with ovarian cancer to identify whether lifestyle is associated with survival to provide guidance for women with this disease.